Durvalumab Plus Chemotherapy Maintains OS Benefit in Advanced Biliary Tract Cancer
July 11th, 2022
Dr. Aiwu Ruth He discusses her biliary tract cancer research presented at ESMO GI
Media Coverage
GI Oncology at ASCO 2022: Tumor Sidedness, ctDNA, and MRD
July 11th, 2022
Dr. John L. Marshall and Dr. Mark A. Lewis discuss the most interesting GI research from ASCO 2022
Use of Circulating Tumor DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers
July 11th, 2022
Circulating tumor DNA (ctDNA) is a promising, non-invasive biomarker with the potential to identify the earliest signs of cancer relapse.
Trends and Disparities in Treatment Approaches for Patients With Locoregional ESCC
June 10th, 2022
Dr. Marshall shared insights on contemporary approaches to treating localized ESCC and existing racial disparities in treatment.
A Survey of Patient Presentation, Testing, and Diagnosis in ESCC
June 10th, 2022
Broad discussion from John Marshall, MD, on the current standards of diagnosis care in esophageal squamous cell carcinoma (ESCC).